O'hagan A - Search Results

1

Calculating partial expected value of perfect information via Monte Carlo sampling algorithms.

Brennan A, Kharroubi S, O'hagan A, Chilcott J. Brennan A, et al. Med Decis Making. 2007 Jul-Aug;27(4):448-70. doi: 10.1177/0272989X07302555. Med Decis Making. 2007. PMID: 17761960 Free article.

2

A comparison of United States and United Kingdom EQ-5D health states valuations using a nonparametric Bayesian method.

Kharroubi SA, O'Hagan A, Brazier JE. Kharroubi SA, et al. Stat Med. 2010 Jul 10;29(15):1622-34. doi: 10.1002/sim.3874. Stat Med. 2010. PMID: 20209481

3

Modelling SF-6D health state preference data using a nonparametric Bayesian method.

Kharroubi SA, Brazier JE, Roberts J, O'Hagan A. Kharroubi SA, et al. J Health Econ. 2007 May 1;26(3):597-612. doi: 10.1016/j.jhealeco.2006.09.002. Epub 2006 Oct 27. J Health Econ. 2007. PMID: 17069909 Free article.

4

Modelling covariates for the SF-6D standard gamble health state preference data using a nonparametric Bayesian method.

Kharroubi S, Brazier JE, O'Hagan A. Kharroubi S, et al. Soc Sci Med. 2007 Mar;64(6):1242-52. doi: 10.1016/j.socscimed.2006.10.040. Epub 2006 Dec 8. Soc Sci Med. 2007. PMID: 17157971

5

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

Chilcott J, McCabe C, Tappenden P, O'Hagan A, Cooper NJ, Abrams K, Claxton K, Miller DH; Cost Effectiveness of Multiple Sclerosis Therapies Study Group. Chilcott J, et al. BMJ. 2003 Mar 8;326(7388):522; discussion 522. doi: 10.1136/bmj.326.7388.522. BMJ. 2003. PMID: 12623909 Free PMC article.

6

Incorporation of uncertainty in health economic modelling studies.

O'Hagan A, McCabe C, Akehurst R, Brennan A, Briggs A, Claxton K, Fenwick E, Fryback D, Sculpher M, Spiegelhalter D, Willan A. O'Hagan A, et al. Pharmacoeconomics. 2005;23(6):529-36. doi: 10.2165/00019053-200523060-00001. Pharmacoeconomics. 2005. PMID: 15960550

7

The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.

Nixon RM, O'Hagan A, Oakley J, Madan J, Stevens JW, Bansback N, Brennan A. Nixon RM, et al. Pharm Stat. 2009 Oct-Dec;8(4):371-89. doi: 10.1002/pst.368. Pharm Stat. 2009. PMID: 19340851

8

Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA.

O'Hagan A, Stevenson M, Madan J. O'Hagan A, et al. Health Econ. 2007 Oct;16(10):1009-23. doi: 10.1002/hec.1199. Health Econ. 2007. PMID: 17173339

9

Bayesian assessment of sample size for clinical trials of cost-effectiveness.

O'Hagan A, Stevens JW. O'Hagan A, et al. Med Decis Making. 2001 May-Jun;21(3):219-30. doi: 10.1177/0272989X0102100307. Med Decis Making. 2001. PMID: 11386629

10

The probability of cost-effectiveness.

O'Hagan A, Stevens JW. O'Hagan A, et al. BMC Med Res Methodol. 2002;2:5. doi: 10.1186/1471-2288-2-5. Epub 2002 Mar 11. BMC Med Res Methodol. 2002. PMID: 11914138 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88 results

Search Page

Filters